

Answering Reviewers – Response to Peer-Review Report

In this manuscript, the authors reported disappointingly low SVR rates (overall SVR rate 45%) in a small cohort of post-OLT patients receiving sofosbuvir and ribavirin for recurrent HCV infection.

Minor comments:

Page 5, line 7: 63% should be 62% (changed in revised manuscript)

Page 6, second paragraph: Despite its pangenotypic property, sofosbuvir was originally approved by FDA for genotypes 1-4 HCV infection. Please verify that. (changed to , “sofosbuvir (SOF), an inhibitor of the HCV NS5B polymerase, was approved by the US Food and Drug Administration for use in combination with RBV, with or without PEG, for the treatment of chronic HCV infection in genotypes 1-4”)

Page 8: Please mention the full name of EOT when it first appears in text. (added full name at first appearance of EOT)

Page 10, line 14: eGFR should be added after 'estimated glomerular filtration rate' here (added in revised manuscript)

Page 10, line 15: [OR =0.95, p =0.01] and [OR =2.43 per mg/dL, p<0.01] (changed estimated glomerular filtration rate to eGFR in revised manuscript)

Page 12, line 11: 'direct acting antivirals' should be changed to 'DAAs' (changed in revised manuscript)